These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Time to Explore Transcatheter Aortic Valve Replacement in Younger, Low-Risk Patients. Sondergaard L JACC Cardiovasc Interv; 2016 Nov; 9(21):2183-2185. PubMed ID: 27744040 [TBL] [Abstract][Full Text] [Related]
5. Analysis of cardiovascular mortality, bleeding, vascular and cerebrovascular events in patients with atrial fibrillation vs. sinus rhythm undergoing transfemoral Transcatheter Aortic Valve Implantation (TAVR). Herold J; Herold-Vlanti V; Sherif M; Luani B; Breyer C; Bonaventura K; Braun-Dullaeus R BMC Cardiovasc Disord; 2017 Dec; 17(1):298. PubMed ID: 29262768 [TBL] [Abstract][Full Text] [Related]
6. Choice of Treatment for Aortic Valve Stenosis in the Era of Transcatheter Aortic Valve Replacement in Eastern Denmark (2005 to 2015). De Backer O; Luk NH; Olsen NT; Olsen PS; Søndergaard L JACC Cardiovasc Interv; 2016 Jun; 9(11):1152-8. PubMed ID: 27209252 [TBL] [Abstract][Full Text] [Related]
11. Late degeneration of transcatheter aortic valves: pathogenesis and management. Barbanti M; Tamburino C EuroIntervention; 2016 Sep; 12(Y):Y33-6. PubMed ID: 27640028 [TBL] [Abstract][Full Text] [Related]
12. Treating the patients in the 'grey-zone' with aortic valve disease: a comparison among conventional surgery, sutureless valves and transcatheter aortic valve replacement. Muneretto C; Bisleri G; Moggi A; Di Bacco L; Tespili M; Repossini A; Rambaldini M Interact Cardiovasc Thorac Surg; 2015 Jan; 20(1):90-5. PubMed ID: 25320140 [TBL] [Abstract][Full Text] [Related]
13. The Incidence and Predictors of Early- and Mid-Term Clinically Relevant Neurological Events After Transcatheter Aortic Valve Replacement in Real-World Patients. Bosmans J; Bleiziffer S; Gerckens U; Wenaweser P; Brecker S; Tamburino C; Linke A; J Am Coll Cardiol; 2015 Jul; 66(3):209-217. PubMed ID: 26184612 [TBL] [Abstract][Full Text] [Related]
14. The risk and extent of neurologic events are equivalent for high-risk patients treated with transcatheter or surgical aortic valve replacement. Gleason TG; Schindler JT; Adams DH; Reardon MJ; Kleiman NS; Caplan LR; Conte JV; Deeb GM; Hughes GC; Chenoweth S; Popma JJ J Thorac Cardiovasc Surg; 2016 Jul; 152(1):85-96. PubMed ID: 27085389 [TBL] [Abstract][Full Text] [Related]
15. When to SAVR in the age of TAVR? A perspective on surgical aortic valve replacement in 2018. Wyler von Ballmoos MC; Barker CM; Reul RM; Dadu R; Ramchandani M; Kleiman NS; Reardon MJ Cardiovasc Revasc Med; 2018 Mar; 19(2):139-141. PubMed ID: 29661491 [No Abstract] [Full Text] [Related]
16. What are the remaining limitations of TAVI? De Biase C; Mastrokostopoulos A; Philippart R; Bonfils L; Berthoumieu P; Dumonteil N J Cardiovasc Surg (Torino); 2018 Jun; 59(3):373-380. PubMed ID: 29557590 [TBL] [Abstract][Full Text] [Related]
19. Changes in thromboinflammatory profiles across the generations of transcatheter aortic heart valves. Sexton T; Alkhasova M; de Beer M; Lynch D; Smyth S J Thromb Thrombolysis; 2019 Feb; 47(2):174-178. PubMed ID: 30484011 [TBL] [Abstract][Full Text] [Related]
20. Nose cone entrapment after transcatheter aortic valve implantation of a CoreValve self-expandable bioprosthesis. Pyxaras SA; Pizzulli L; Gerckens U J Cardiovasc Med (Hagerstown); 2016 Dec; 17 Suppl 2():e183-e184. PubMed ID: 28482354 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]